Scientific Advances and New Frontiers in Mesothelioma Therapeutics

Luciano Mutti, Tobias Peikert, Bruce W.S. Robinson, Arnaud Scherpereel, Anne S. Tsao, Marc de Perrot, Gavitt A. Woodard, David M. Jablons, Jacinta Wiens, Fred R. Hirsch, Haining Yang, Michele Carbone, Anish Thomas, Raffit Hassan

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.

Original languageEnglish (US)
Pages (from-to)1269-1283
Number of pages15
JournalJournal of Thoracic Oncology
Volume13
Issue number9
DOIs
StatePublished - Sep 2018

    Fingerprint

Keywords

  • Biomarkers
  • Chemotherapy
  • Immunotherapy
  • Malignant pleural mesothelioma
  • Oncology therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Mutti, L., Peikert, T., Robinson, B. W. S., Scherpereel, A., Tsao, A. S., de Perrot, M., Woodard, G. A., Jablons, D. M., Wiens, J., Hirsch, F. R., Yang, H., Carbone, M., Thomas, A., & Hassan, R. (2018). Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology, 13(9), 1269-1283. https://doi.org/10.1016/j.jtho.2018.06.011